Treatment may help people with type 1 diabetes make insulin again

Date:

Share this article:

Del denne artikel:

Researchers are testing a new therapy designed to help people with type 1 diabetes produce insulin on their own again.

Living with type 1 diabetes means planning every meal, counting carbohydrates and watching blood sugar levels around the clock. Even with modern tools, it remains a condition that shapes everyday life.

Now a research team in the United States is working on an approach that aims to rebuild what the body has lost instead of simply managing the damage.

Rebuilding what was destroyed

At the Medical University of South Carolina, scientist Leonardo Ferreira is leading a project funded with $1 million from Breakthrough T1D.

The goal is to restore insulin production by transplanting lab-grown beta cells, which are normally destroyed by the immune system in people with type 1 diabetes.

Also read: Younger adults face unexpected rise in heart attack mortality

Unlike traditional islet transplants, which rely on donor tissue, these new cells are produced from stem cells in the laboratory. That could solve the long-standing shortage of donor material.

Training the immune system

The second part of the strategy focuses on protection. Ferreira and collaborators Holger Russ at the University of Florida and Michael Brehm at the University of Massachusetts Medical School are engineering regulatory T cells to defend the transplanted beta cells.

These modified immune cells are designed to recognize and shield the new insulin-producing cells from attack.

If successful, the therapy could reduce or even remove the need for lifelong immunosuppressive drugs, which often carry serious side effects.

Also read: Do you eat eggs every week? Here's how they can affect your blood pressure

Early tests in preclinical models have shown protection lasting up to a month. Researchers are now studying how to extend that effect and move closer to human trials.

If the concept works, it may represent a shift from lifelong insulin dependence toward a durable, cell-based treatment for type 1 diabetes.

Sources: Science Daily and MUSC

Also read: Free nicotine products at work: Tech companies hope for more productive employees

Also read: This McDonald’s burger contains more than two-thirds of a day’s calories

This article is made and published by Mie Hermansen, who may have used AI in the preparation.

Other articles

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.

Your gut bacteria may spread to the people around you more easily than anyone realized

A new Nature study finds gut microbes spread between people, sometimes across continents, faster than expected.

Low vitamin C may be quietly speeding up how fast your brain ages

A study of 2,044 older adults links lower plasma vitamin C to shrinking brain volume and weaker memory-network wiring.

Why rheumatoid arthritis attacks some joints and not others: The answer starts before birth

Oxford scientists say certain finger joints may be biologically primed for the disease before you are born.

GLP-1 drugs like Ozempic may now be an option for a group of patients long left out

The 2026 American Diabetes Association guidance opens GLP-1 therapy to a new patient group.

Your gut bacteria may spread to the people around you more easily than anyone realized

A new Nature study finds gut microbes spread between people, sometimes across continents, faster than expected.

Low vitamin C may be quietly speeding up how fast your brain ages

A study of 2,044 older adults links lower plasma vitamin C to shrinking brain volume and weaker memory-network wiring.